Clinical trial
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma…
NCT00021307 · Fox Chase Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00021307 |
|---|---|
| Title | Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | Phase I/II Trial Of Temozolomide And Carboplatin In Recurrent Glioblastoma Multiforme |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | carboplatin, temozolomide |
| Enrollment | 0 |
| Primary completion | Apr 1, 2002 |
| Completion | Apr 1, 2002 |
| First posted | Jan 14, 2004 |
| Last update posted | Jul 11, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: